Showing results (1-10 of 13) with videos related to
Sort By:
Pageof 2
Obstetrics and Gynecology Clinics of North America|September 12, 2013
Special considerations in early-stage breast cancer patients and survivorsAmelia B ZelnakMethods in Molecular Medicine|December 19, 2007
Clinical pharmacology and use of microtubule-targeting agents in cancer therapyAmelia B ZelnakBiodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|July 14, 2007
Targeting angiogenesis in advanced breast cancerAmelia B Zelnak, Ruth M O'ReganCancer|July 25, 2014
Management of patients with HER2-positive metastatic breast cancer: is there an optimal sequence of HER2-directed approaches?Amelia B Zelnak, Kari B WisinskiOncology (Williston Park, N.Y.)|May 22, 2013
Genomic subtypes in choosing adjuvant therapy for breast cancerAmelia B Zelnak, Ruth M O'ReganJournal of the National Comprehensive Cancer Network : JNCCN|August 19, 2015
Optimizing Endocrine Therapy for Breast CancerAmelia B Zelnak, Ruth M O'ReganClinical Breast Cancer|July 29, 2014
High pathologic complete response in Her2-positive, early-stage breast cancer to a novel nonanthracycline neoadjuvant chemotherapyAmelia B Zelnak, Petros Nikolinakos, Jayanthi Srinivasiah, et al.International Journal of Breast Cancer|August 13, 2015
Locoregional Recurrence Risk in Breast Cancer Patients with Estrogen Receptor Positive Tumors and Residual Nodal Disease following Neoadjuvant Chemotherapy and Mastectomy without Radiation TherapyShravan Kandula, Jeffrey M Switchenko, Saul Harari, et al.Clinical Breast Cancer|January 22, 2013
Final results from phase II trial of neoadjuvant docetaxel and capecitabine given sequentially or concurrently for HER2-negative breast cancersAmelia B Zelnak, Toncred M Styblo, Monica Rizzo, et al.Annals of Surgical Oncology|December 5, 2014
The 21-gene recurrence score and locoregional recurrence in breast cancer patientsNaresh K Jegadeesh, Sunjin Kim, Roshan S Prabhu, et al.Pageof 2